Phio Pharmaceuticals Corp
PHIO
Company Profile
Business description
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Contact
11 Apex Drive
Suite 300A PMB 2006
MarlboroughMA01752
USAT: +1 508 767-3861
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,006.80 | 116.00 | 1.30% |
CAC 40 | 7,822.67 | 0.67 | 0.01% |
DAX 40 | 24,289.51 | 81.42 | -0.33% |
Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
FTSE 100 | 8,992.12 | 19.48 | 0.22% |
HKSE | 24,825.66 | 326.71 | 1.33% |
NASDAQ | 20,895.65 | 10.01 | 0.05% |
Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
S&P 500 | 6,296.79 | 0.57 | -0.01% |
S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
SSE Composite Index | 3,534.48 | 17.66 | 0.50% |